Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07803744) titled 'A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity' on Sept. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Diabetes Mellitus, Type 1
Overweight
Obesity
Intervention:
Drug: Tirzepatide
Drug: Acetaminophen
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 18
Countries of Recruitment:
United States
To ...